2023—A Bumper Year for the Treatment and Science of Alzheimer's
Last summer saw a first: the traditional approval of a disease-modifying Alzheimer's therapy. Solid progress on biomarkers, and a flourishing of basic research, made for a good year.
48 RESULTS
Sort By:
Last summer saw a first: the traditional approval of a disease-modifying Alzheimer's therapy. Solid progress on biomarkers, and a flourishing of basic research, made for a good year.
Axons touch arterioles, releasing glutamate that makes smooth muscle cells relax. This increases cerebral blood flow in mice.
A U.K. Biobank analysis generated 15 risk factors for young-onset dementia. Many factors also correlated with late-onset disease.